The Aim is to Identify Recurrent Genomic Mutations and/or Predisposing Polymorphisms in Patients With Sporadic Cases of Multiple Myeloma

Study Overview
=================
Brief Summary
-----------------
There is a growing body of data suggesting that the the risk of developing multiple myeloma, or myelomagenesis, is associated with genetic alterations occurring in the tumor cells. A limited number of candidate genes and polymorphisms have been reported in patients with this disease. In this study the investigators will compare the genetic information obtained on purified abnormal plasmocytes obtained from patients with multiple myeloma with available public databases in an effort to identify and if possible validate the role of certain mutations and/or polymorphisms in myelomagenesis. Plasmocytes will be obtained by immunomagnetic enrichment using CD138+ beads.

Official Title
-----------------
Analysis of Genomic Alterations in Sporadic Cases of Multiple Myeloma

Conditions
-----------------
Multiple Myeloma

Intervention / Treatment
-----------------
* Genetic: DNA sequencing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosis of multiple myeloma availability of abnormal plasmocytes Exclusion Criteria: - none

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients with a diagnosis of multiple myeloma<br>This study will involve a single patient group, namely patients with a diagnosis of multiple myeloma diagnosed by a bone marrow aspirate with cytological analysis of the bone marrow smear.Bone marrow samples obtained during the routine follow-up will undergo plasmocyte enrichment using immunopurification using CD138+ beads and nucleic acids will be extracted for sequencing. | Genetic: DNA sequencing<br>* The aim of this study is to perform DNA sequencing on abnormal plasmocytes obtained from patients with multiple myeloma, in order to identify alterations which are associated with the existence of this disease. DNA analyses will be performed in a single experiment once all samples have been collected.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| DNA mutations associated with the existence of multiple myeloma | DNA data acquired in myeloma patient samples will be compared to those of healthy subjects using publically available databases. | baseline, pre-intervention/procedure/surgery | 
| DNA mutations associated with the existence of multiple myeloma | DNA data acquired in myeloma patient samples will be compared to those of healthy subjects using publically available databases. | during the intervention/procedure/surgery | 
| DNA mutations associated with the existence of multiple myeloma | DNA data acquired in myeloma patient samples will be compared to those of healthy subjects using publically available databases. | immediately after the intervention/procedure/surgery | 
| DNA mutations associated with the existence of multiple myeloma | DNA data acquired in myeloma patient samples will be compared to those of healthy subjects using publically available databases. | at 1 year | 
| DNA mutations associated with the existence of multiple myeloma | DNA data acquired in myeloma patient samples will be compared to those of healthy subjects using publically available databases. | up to 24 weeks | 
| DNA mutations associated with the existence of multiple myeloma | DNA data acquired in myeloma patient samples will be compared to those of healthy subjects using publically available databases. | through study completion, an average of 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
genetic predisposition, mutations, sporadic, multiple myeloma